CoChat
Sign Up
Cited by 97Cystic Fibrosis Research AdvancesObesity, Physical Activity, DietChronic Obstructive Pulmonary Disease (COPD) Research

Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: A single-center analysis

Open access
Harindhanavudhi, Tasma, Wang, Qi, Dunitz, Jordan, Moran, Antoinette, Moheet, Amir·2020·Journal of Cystic Fibrosis
DOI 10.1016/j.jcf.2019.10.004PMC PMC7680669
Open this paper in CoChat — free account

Abstract

Background The relation between malnutrition and pulmonary death in patients with cystic fibrosis (CF) has resulted in intensive nutritional intervention over the last few decades, leading to a significant decline in underweight and the emergence of overweight/obesity as a potential new problem. Methods We performed a cross-sectional database analysis of 484 adults with CF seen at the University of Minnesota CF Center between January 2015-January 2017, to determine the prevalence and pulmonary/cardiovascular risk factors associated with overweight and obesity in this population. Results Mean age was 35.2 ± 11.6 years. 5.2% were underweight (BMI<18.5 kg/m 2), 62.6% normal weight (BMI ≥ 18.5-24.9 kg/m 2), 25.6% overweight (BMI ≥ 25-29.9 kg/m 2) and 6.6% obese (BMI ≥ 30 kg/m 2). In the subgroup with severe genotypes, 25% had BMI ≥ 25 kg/m 2. In the entire cohort, overweight/obese were likely to be older (OR = 1.04, p < 0.0001) and to have a mild CFTR genotype (OR = 3.33, p = 0.0003) and modestly elevated triglyceride levels (OR = 1.008, p < 0.0001). The prevalence of hypertension was higher in overweight (25%) and obese (31%) than normal (17%) or underweight (16%), p = 0.01. Total cholesterol levels were higher in overweight/obese versus normal/underweight (144-147 vs 123-131 mg/dL, p = 0.04) as were LDL levels (70-71 vs 53-60 mg/dL, p = 0.02), but all were within the normal range. Percent predicted FEV1 was higher in overweight/obese (78-81%) versus underweight (59%) and normal (70%), p < 0.0001, and overweight/obese experienced significantly fewer acute pulmonary exacerbations. Conclusions Overweight/obesity is common in adults with CF including those with severe genotypes. Lung function is better in the overweight/obese and lipid levels are within the normal range, albeit higher than in normal/underweight.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcf.2019.10.004

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Studies have shown that with the advent of new CFTR modulators, which prolong life and improve weight gain, the percent of cystic fibrosis individuals with BMI over 25 has steadily increased.

    “Studies have shown that with the advent of new CFTR modulators, which not only prolong life but improve weight gain, percent of CF individuals with BMI over 25 has steadily increased.”

    From Eating disorders and body image in cystic fibrosis (2021) · cites this paper as [34]

    The Discussion reports higher BMI and a greater prevalence of overweight and obesity than in earlier CF cohorts. It says new CFTR drugs might help explain the difference and reports that they can increase weight, but this cohort found no association between modulator treatment and body weight. The cited passages do not establish that modulators prolonged life or caused a steady increase in the percentage with BMI over 25. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 23

  1. [1]Elborn JS. Cystic fibrosis. Lancet 2016; 388: 2519– 31. doi: 10.1016/S0140-6736(16)00576-6. 27140670 · DOI
  2. [2]Li L, Somerset S. Digestive system dysfunction in cystic fibrosis: challenges for nutrition therapy. Dig Liver Dis 2014; 46: 865– 74. 25053610
  3. [3]Culhane S, George C, Pearo B, Spoede E. Malnutrition in cystic fibrosis: a review. Nutr Clin Pract 2013; 28: 676– 83. 24170579
  4. [4]Steinkamp G, Wiedemann B. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 2002; 57: 596– 601. 12096202 PMC1746376
  5. [5]Jarad NA, Higgs S, Jeffcote T, Giles K. Factors associated with reduced FEV1 in adult patients with cystic fibrosis in a relatively affluent area. Chron Respir Dis 2005; 2: 133– 7. doi: 10.1191/1479972305cd065oa. 16281436 · DOI
  6. [6]Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H, Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry. Eur Respir J 2014; 43: 125– 33. doi: 10.1183/09031936.00166412. 23598952 · DOI · Paper page
  7. [7]Hauschild DB, Rosa AF, Ventura JC, Barbosa E, Moreira EAM, Ludwig Neto N, Moreno YMF. Association of nutritional status with lung function and morbidity in children and adolescents with cystic fibrosis: a 36-month cohort study. Rev Paul Pediatr 2018; 36: 8. doi: 10.1590/1984-0462/;2018;36;1;00006. PMC5849371 29412427 · DOI
  8. [9]Yen EH, Quinton H, Borowitz D. Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. J Pediatr 2013; 162: 530– 5. 23062247
  9. [10]Castellani C, Duff A, Bell S, Heijerman H, Munck A, Ratjen F, ECFS best practice guidelines: the 2018 revision. J Cyst Fibrosis 2018; 17: 153– 78. doi: 10.1016/j.jcf.2018.02.006. 29506920 · DOI · Paper page
  10. [11]Turck D, Braegger C, Colombo C, Declercq D, Morton A, Pancheva R. ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr 2016; 35: 557– 77. doi: 10.1016/j.clnu.2016.03.004. 27068495 · DOI
  11. [12]Stephenson AL, Mannik LA, Walsh S, Brotherwood M, Robert R, Darling PB, Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study. Am J Clin Nutr 2013; 97: 872– 7. 23388659
  12. [13]Hanna RM, Weiner DJ. Overweight and obesity in patients with cystic fibrosis: a center-based analysis. Pediatr Pulmonol 2015; 50: 35– 41. 24757043
  13. [16]Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the american diabetes association and a clinical practice guideline of the cystic fibrosis foundation, endorsed by the pediatric endocrine society. Diabetes Care 2010; 33: 2697– 708. doi: 10.2337/dc10-1768. 21115772 PMC2992215 · DOI
  14. [17]Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population.. Am J Respir Crit Care Med 1999; 159: 179– 87. 9872837
  15. [18]Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, Ramalho AS, Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 2013; 45: 1160– 7. 23974870 PMC3874936
  16. [19]Lewis C, Blackman S, Nelson A, Oberdorfer E, Wells D, Dunitz J, Diabetes-related mortality in adults with cystic fibrosis: role of genotype and sex. Am J Respir Crit Care Med 2015; 191: 194– 200. doi: 10.1164/rccm.201403-0576OC. 25479583 PMC4347432 · DOI
  17. [20]Kastner-Cole D, Palmer CN, Ogston SA, Overweight and obesity in deltaF508 homozygous cystic fibrosis. J Pediatr 2005; 147: 402– 4. 16182686
  18. [21]Coderre L, Fadainia C, Belson L, Belisle V, Ziai S, Maillhot G, LDL-cholesterol and insulin are independently associated with body mass index in adult cystic fibrosis patients. J Cyst Fibros 2012; 11: 393– 7. doi: 10.1016/j.jcf.2012.03.006. 22503692 · DOI · Paper page
  19. [22]Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Tezacaftor-Ivacaftor in residual-function heterozygotes with cystic fibrosis. N Engl J Med 2017; 377: 2024– 35. doi: 10.1056/NEJMoa1709847. 29099333 PMC6472479 · DOI · Paper page
  20. [23]Borowitz D, Lubarsky B, Wilschanski M, Munck A, Gelfond D, Bodewes F, Schwarzenberg SJ. Nutritional status improved in cystic fibrosis patients with the G551D mutation after treatment with ivacaftor. Dig Dis Sci 2016; 61((1) 1): 198– 207. doi: 10.1007/s10620-015-3834-2. 26250833 · DOI
  21. [25]Dray X, Kanaan R, Bienvenu T, Desmazes-Dufeu N, Dusser D, Marteau P, Malnutrition in adults with cystic fibrosis. Eur J Clin Nutr 2005; 59: 152– 4. doi: 10.1038/sj.ejcn.1602039. 15367921 · DOI
  22. [26]Rhodes B, Nash E, Tullis E, Pencharz P, Brotherwood M, Dupuis A, Stephenson A. Prevalence of dyslipidemia in adults with cystic fibrosis. J Cyst Fibros 2010; 9: 24– 8. doi: 10.1016/j.jcf.2009.09.002. 19875344 · DOI
  23. [28]Saxby N, Painter C, Kench A, King S, Crowder T, van der Haak N. and the australian and new zealand cystic fibrosis nutrition guideline authorship group. Nutrition guidelines for cystic fibrosis in Australia and New Zealand. Bell Scott C, editor. Sydney: Thoracic Society of Australia and New Zealand; 2017. 31175004

Cited by

Sorted by citations

Authors
Harindhanavudhi, T., Wang, Q., Dunitz, J., Moran, A., & Moheet, A.
Affiliations
University of Minnesota (US)
Corresponding author
Harindhanavudhi, Tasma
ORCID
Venue
Journal of Cystic Fibrosis
Publisher
Elsevier BV
Published
2020-01
Volume
19
Issue
1
Pages
139-145
ISSN
1569-1993 (ISSN-L)
DOI
10.1016/j.jcf.2019.10.004
PMC
PMC7680669
OpenAlex
W2987619647
Cited by
97
References
3
Citations by year
2026: 12 · 2025: 13 · 2024: 11 · 2023: 18 · 2022: 22 · 2021: 13 · 2020: 7 · 2019: 1
FWCI
7.91
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Cystic Fibrosis (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
Cystic Fibrosis Foundation
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
adults with cystic fibrosis, overweight, obesity, prevalence, risk factors, CFTR genotype, hypertension, serum lipids, lung function, FEV1, pulmonary exacerbations, nutritional status, malnutrition
MeSH terms
Correlation of Data, Heart Disease Risk Factors, Adult, Cholesterol, Cystic Fibrosis, Female, Humans, Male, Nutritional Status, Obesity, Respiratory Function Tests, Thinness, United States, Body Mass Index, Prevalence, Malnutrition, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review